本文選題：低分子肝素　切入點：巰基殼聚糖　出處：《山西醫(yī)科大學(xué)》2014年碩士論文　論文類型：學(xué)位論文

【摘要】：隨著生物技術(shù)的飛速進(jìn)展，越來越多的大分子如蛋白質(zhì)、多肽、多糖和核酸類藥物應(yīng)用于臨床。這類藥物毒副作用小、療效確切，但大都具有多重胃腸道吸收屏障而限制了口服應(yīng)用。低分子肝素(LMWH)是治療深靜脈血栓的大分子藥物，在胃酸中不穩(wěn)定，小腸中相對穩(wěn)定，水溶性強、分子量大及荷負(fù)電荷的特點使其難以透過胃腸粘膜吸收，臨床只能靜脈注射給藥。巰基殼聚糖(TCS)是殼聚糖(CS)的衍生物，具有生物可降解、低毒、抑酶、促粘膜吸收及生物粘附等特性，但生物粘附作用比CS更強。 本文以大分子藥物L(fēng)MWH為模型藥物，，以TCS為載體材料，羥丙甲基纖維素鄰苯二甲酸酯(HP-55)為交聯(lián)劑，采用離子交聯(lián)技術(shù)制備LMWH pH敏感TCS納米粒。以期能通過pH敏感納米粒酸性條件下不溶解及空間障礙保護(hù)低分子肝素免受胃酸和消化酶降解；利用TCS促進(jìn)滲透、增強粘附、抑酶作用，以增加LMWH的粘膜透過，達(dá)到提高其口服生物利用度的目的。 本文主要研究內(nèi)容如下： 1、TCS的合成與表征 以CS為載體材料，碳二亞胺為催化劑，與巰基乙酸反應(yīng)合成TCS。建立Ellman’s試劑紫外分光光度法，測定TCS中巰基含量為(396.97±54.54) μmol/g。以巰基含量為指標(biāo)考察影響合成的因素，用紅外光譜分析法表征。 2、LMWH pH敏感TCS納米粒的制備及表征 以TCS為載體材料、HP-55為交聯(lián)劑，采用離子交聯(lián)法制備LMWH pH敏感TCS納米粒。采用透射電子顯微鏡觀察納米粒形態(tài)為類圓球形；粒度儀測定納米粒的平均粒徑(329.6±7.3) nm、PDI (0.185±0.01)、Zeta電勢(34.5±2.25)mV。 3、LMWH體外分析方法的建立 建立天青A紫外分光光度法測定LMWH含量。并進(jìn)行了重復(fù)性、精密度和回收率等方法學(xué)考察。分析方法準(zhǔn)確可靠，可用于LMWH體外樣品的分析。測定LMWH pH敏感TCS納米粒載藥量為(12.463±0.003) IU/mg、包封率為(97.75±0.02)%。 4、LMWH pH敏感TCS納米粒的體外評價 透析法考察納米粒體外藥物釋放，實驗結(jié)果表明pH敏感TCS納米粒在酸性條件下能顯著減少藥物的釋放；Franz擴散池法考察納米粒藥物腸粘膜透過作用，藥物腸粘膜累積透過量：pH敏感巰基殼聚糖納米粒、巰基殼聚糖納米粒＞pH敏感殼聚糖納米粒＞藥物溶液；Mett毛細(xì)玻管法考察納米粒的抑酶作用，pH敏感巰基殼聚糖納米粒抑酶作用強于pH敏感殼聚糖納米粒和藥物溶液；體外孵化實驗考察納米粒對藥物的保護(hù)作用，pH敏感巰基殼聚糖納米粒對藥物的保護(hù)作用強于巰基殼聚糖納米粒和藥物溶液。 5、LMWH pH敏感TCS納米粒的體內(nèi)評價 激光掃描共聚焦顯微分析技術(shù)考察大鼠口服熒光標(biāo)記納米粒后腸粘膜粘附作用，pH敏感TCS納米粒腸粘膜熒光強度明顯高于藥物溶液、pH敏感CS納米粒和TCS納米粒；大鼠口服pH敏感TCS納米粒后，活化部分凝血活酶時間（APTT）顯著延長，生物利用度顯著提高，表明抗凝作用增強、LMWH口服吸收量提高。
[Abstract]:With the rapid development of biotechnology, more and more macromolecules such as proteins, peptides, polysaccharides and nucleic acids are used in clinic. Low molecular weight heparin (LMWH) is a macromolecular drug for the treatment of deep venous thrombosis, which is unstable in gastric acid, relatively stable in small intestine and strong in water solubility. The characteristics of high molecular weight and negative charge make it difficult to be absorbed through gastrointestinal mucosa, so it can only be given intravenously in clinic. Thioglycol-chitosan (TCSs) is a derivative of chitosan (CSS), which is biodegradable, low toxic and enzyme suppressive. Promote mucosal absorption and biological adhesion, but the biological adhesion is stronger than CS. In this paper, macromolecular drug LMWH was used as model drug, TCS as carrier material and hydroxypropylcellulose phthalate (HP-55) as crosslinking agent. LMWH pH sensitive TCS nanoparticles were prepared by ion crosslinking technique, which could protect low molecular weight heparin from gastric acid and digestive enzyme degradation through pH sensitive nanoparticles in acidic condition. In order to increase the mucosal permeability of LMWH and increase its oral bioavailability. The main contents of this paper are as follows:. Synthesis and characterization of TCS. Using CS as carrier material and carbodiimide as catalyst, TCS was synthesized by reaction with thioglycolic acid. The UV spectrophotometric method of Ellman's reagent was established. The content of thiol in TCS was 396.97 鹵54.54 渭 mol / g. It was characterized by infrared spectroscopy. Preparation and characterization of LMWH pH sensitive TCS nanoparticles. Using TCS as carrier material, LMWH pH sensitive TCS nanoparticles were prepared by ion crosslinking method. The morphology of LMWH nanoparticles was observed by transmission electron microscopy (TEM), and the average particle size of LMWH nanoparticles was determined by particle size analyzer. The average particle size of LMWH was 329.6 鹵7.3) nmPDI 0.185 鹵0.01nmPe (34.5 鹵2.25mV). Establishment of in vitro analytical method for LMWH. A UV spectrophotometric method for the determination of LMWH was established. The methods of repeatability, precision and recovery were investigated. The method was accurate and reliable. It can be used for the analysis of LMWH samples in vitro. The drug loading capacity of LMWH pH sensitive TCS nanoparticles is 12.463 鹵0.003). The encapsulation efficiency is 97.75 鹵0.02%. In vitro evaluation of TCS nanoparticles with LMWH pH sensitivity. In vitro drug release of nanoparticles was investigated by dialysis. The results showed that pH sensitive TCS nanoparticles could significantly reduce drug release under acidic conditions. Franz diffusion cell method was used to investigate the intestinal mucosal permeability of nanoparticles. Drug intestinal mucosal cumulative transmittance: ph sensitive mercapto chitosan nanoparticles, The inhibition effect of mercapto chitosan nanoparticles > pH sensitive chitosan nanoparticles > drug solution / mett capillary tube method was studied. The inhibition effect of pH sensitive chitosan nanoparticles was stronger than that of pH sensitive chitosan nanoparticles and drug solutions. In vitro incubation experiments were conducted to investigate the protective effect of nanoparticles on drugs. The protective effect of pH sensitive mercapto chitosan nanoparticles was stronger than that of mercapto chitosan nanoparticles and drug solutions. In vivo evaluation of TCS nanoparticles sensitive to LMWH pH. Laser scanning confocal microscopy study on intestinal mucosal adhesion of TCS nanoparticles after oral fluorolabeling in rats the fluorescence intensity of pH sensitive TCS nanoparticles was significantly higher than that of pH sensitive CS nanoparticles and TCS nanoparticles in drug solution. After oral administration of pH sensitive TCS nanoparticles, the activated partial thromboplastin time (APTT) was significantly prolonged and the bioavailability was significantly increased, which indicated that the anticoagulant effect was enhanced and the oral absorption of LMWH was increased.
【學(xué)位授予單位】：山西醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2014
【分類號】：R944.9

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 姚金鳳;郭晨陽;楊紅;譚桂蓮;薛明;;殼聚糖納米粒在藥物輸送中的應(yīng)用研究進(jìn)展[J];國際藥學(xué)研究雜志;2013年01期

2 計巖;趙敏;鄔桂玉;;胸腺素β4殼聚糖納米粒的制備及其對NF-κB表達(dá)調(diào)節(jié)治療兔角膜創(chuàng)傷[J];第三軍醫(yī)大學(xué)學(xué)報;2013年14期

3 林箐;王夢馨;吳佳奕;彭強;張志榮;;殼聚糖納米粒Zeta電位與載藥量關(guān)系初探[J];華西藥學(xué)雜志;2012年03期

4 李夜平;徐云;程曉農(nóng);吳士龍;劉宏飛;;反相細(xì)乳液交聯(lián)法制備裂隙結(jié)構(gòu)殼聚糖納米粒[J];江蘇大學(xué)學(xué)報(自然科學(xué)版);2014年01期

5 俞淑文,王鳳山,翟光喜,姬勝利,曹吉超;應(yīng)用比濁法測定低分子肝素鈉的含量[J];山東大學(xué)學(xué)報(醫(yī)學(xué)版);2003年02期

6 王彥;賴克方;張巧;馬千里;王長征;;離子凝膠法制備殼聚糖納米微粒的影響因素分析[J];山東醫(yī)藥;2011年27期

7 鞏慧敏;馮澤岸;邵婷璣;廖明琪;喬華;;異甘草素固體脂質(zhì)納米粒中低分子肝素鈉包封率的測定[J];中國生化藥物雜志;2012年04期

8 沈素晶;黃來強;沈素云;張戰(zhàn)鋒;曾小偉;黃憲章;;青蒿琥酯納米顆粒的制備及其體外抑制腫瘤細(xì)胞增殖的作用研究[J];現(xiàn)代生物醫(yī)學(xué)進(jìn)展;2013年23期

9 錢嫦云;徐曉芬;郭愛潔;郭圣榮;;季磷鹽殼聚糖的合成及其水溶性研究[J];現(xiàn)代生物醫(yī)學(xué)進(jìn)展;2014年03期

10 婁月芬,王晶,馬佳珍,李方;生物可降解的聚合物納米粒的研究進(jìn)展[J];醫(yī)藥導(dǎo)報;2005年04期

本文編號：1560762